The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CLPBF | -27.54% | -48.91% | -12.57% | -25% |
| S&P | +14.39% | +76.41% | +12.02% | +483% |
Coloplast A/S develops, manufactures, and markets medical products. It operates through the following segments: Chronic Care, Interventional Urology and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Interventional Urology segment covers the sale of urological products, including disposable products. The Wound & Skin Care segment covers the sale of wound and skin care products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.
No news articles found for Coloplast A/s.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.10B | 9.2% |
| Gross Profit | $737.94M | 8.6% |
| Gross Margin | 67.23% | -0.4% |
| Market Cap | $18.86B | -22.7% |
| Market Cap / Employee | $1.12M | 0.0% |
| Employees | 16.9K | 1.6% |
| Net Income | $217.72M | 45.8% |
| EBITDA | $341.15M | 6.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $176.90M | 40.6% |
| Accounts Receivable | $707.43M | 10.5% |
| Inventory | 606.8 | 19.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.36B | 96.8% |
| Short Term Debt | $582.27M | -43.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 8.42% | -1.8% |
| Return On Invested Capital | 23.61% | -8.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $290.03M | 17.3% |
| Operating Free Cash Flow | $348.01M | 21.2% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 35.97 | 35.91 | 35.85 | 31.97 | -7.71% |
| Price to Book | 10.93 | 8.32 | 7.35 | 7.43 | -18.17% |
| Price to Sales | 5.90 | 5.25 | 4.67 | 4.59 | -25.77% |
| Price to Tangible Book Value | -11.14 | -9.88 | -8.98 | -8.75 | -33.45% |
| Price to Free Cash Flow TTM | 1850.64 | 322.90 | 1074.18 | - | |
| Enterprise Value to EBITDA | 86.74 | 73.83 | 61.45 | 67.81 | -20.32% |
| Free Cash Flow Yield | 0.1% | 0.3% | 0.1% | - | |
| Return on Equity | 27.3% | 23.9% | 20.6% | 28.1% | -13.16% |
| Total Debt | $3.51B | $3.81B | $3.56B | $3.95B | 43.84% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
